A stock sale and confusion regarding its parent company are factors dragging down the stock.
Any euphoria after the biotech stock's big jump yesterday didn't last long.
/PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to...
The company is walling off subsidiary Scilex from its bankruptcy proceedings.
/PRNewswire/ -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to...
A bankruptcy filing is weighing on the drugmaker's shares today.
Wall Street is bullish on these two beaten-down healthcare stocks.
Markets are looking for direction in early trading before a holiday weekend. Here are some of the popular stories MarketBeat analysts were covering this week.
Sorrento Therapeutics is on the move following preliminary results from its subsidiary Scilex. Scilex is making money with the company's 1st product to market
Sorrento Therapeutics: Q3 Earnings Snapshot